2022 ESMO:DZD1516 International Multicenter Breast Cancer Clinical Study Results Positive

The 2022 Annual Meeting of the European Society of Oncology (ESMO) published safety and pharmacokinetic data

Research Tips:

DZD1516 has good safety, tolerability, pharmacokinetic properties, excellent blood-brain barrier penetration, and shows initial antitumor activity

Twice-daily (BID) of 250 mg was determined to be MTD, and doses of 250 mg BID and below were not reported for dose-limit toxicity (DLT) and adverse events associated with inhibition of wild-type EGFR

In patients, the Kpuu, CSF (ratio of cerebrospinal fluid to free drug concentrations in plasma) of DZD1516 was 2.

Eighteen patients completed tumor evaluation after at least one dose, and among patients who had previously received median 7-line antineoplastic therapy (86% had received HER2 TKI treatment), the best antineoplastic efficacy of DZD1516 monotherapy intracranial, intracranial, and overall was disease-stable

*As of February 20, 2022

Patients with advanced HER2-positive breast cancer have up to 60% of brain metastases and have a very poor

Dr.